Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

PU-H71

PU-H71
Contact us for more batch information
Select Batch
Purity:98.31%
Resource Download

PU-H71

Catalog No. T6960Cas No. 873436-91-0
PU-H71 is an effective selective HSP90 inhibitor with an IC50 of 51 nM.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$33In Stock
5 mg$59In Stock
50 mg$1987-10 days
100 mg$3547-10 days
1 mL x 10 mM (in DMSO)$107In Stock
Bulk & Custom
Add to Cart

Product Introduction

Bioactivity
Description
PU-H71 is an effective selective HSP90 inhibitor with an IC50 of 51 nM.
In vitro
PU-H71(1 μ M) potently inhibits the growth of triple negative breast cancer (TNBC) cell lines MDA-MB-468, MDA-MB-231, and HCC-1806, with IC50 values of 65, 140, and 87 nM, respectively. PU-H71(1 μ M) kills 80%, 65%, and 80% of MDA-MB-468, MDA-MB-231, and HCC-1806 cells, respectively[1].
In vivo
MDA-MB-231 model treated with PU-H71 at a dose of 75 mg/kg was 100% fully effective. After 37 days of treatment, tumor was replaced by scar tissue, accompanied by a reduction in many proliferative and anti apoptotic molecules, such as EGFR, HER3, Raf-1, Akt, and p-Akt, which decreased by 80%, 95%, 99%, 80%, and 65%, respectively. PU-H71 (75 mg/kg, three times a week) inhibits tumor growth by 96%, reduces tumor cell proliferation by 60%, decreases activated Akt associated with survival and high invasive potential by 85%, and increases apoptosis by 6-fold[1].
Chemical Properties
Molecular Weight512.37
FormulaC18H21IN6O2S
Cas No.873436-91-0
Storage & Solubility Information
Storagestore at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 46.1 mg/mL (89.9 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.9517 mL9.7586 mL19.5171 mL97.5857 mL
5 mM0.3903 mL1.9517 mL3.9034 mL19.5171 mL
10 mM0.1952 mL0.9759 mL1.9517 mL9.7586 mL
20 mM0.0976 mL0.4879 mL0.9759 mL4.8793 mL
50 mM0.0390 mL0.1952 mL0.3903 mL1.9517 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords